<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120917">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779271</url>
  </required_header>
  <id_info>
    <org_study_id>Plb CD 301 Version 3.10</org_study_id>
    <nct_id>NCT01779271</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Pelubiprofen &amp; Loxoprofen in Patients With Upper Respiratory Tract Infection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3
      Clinical trial to assess the efficacy and safety of Pelubiprofen Compared to Loxoprofen in
      patients with Acute upper respiratory infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Changes in Body temperature from baseline</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6 Hour</time_frame>
  </primary_outcome>
  <condition>Acute Upper Respiratory Infection</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Pelubiprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Loxoprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen</intervention_name>
    <arm_group_label>Pelubiprofen</arm_group_label>
    <other_name>Pelubiprofen 30 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxoprofen</intervention_name>
    <arm_group_label>Loxoprofen</arm_group_label>
    <other_name>Loxoprofen 60mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 15 years old

          2. Male and Female

          3. Patients with fever over 38.0Â°C due to cold (acute upper respiratory tract infection)

          4. Patients with upper respiratory tract infection outbreak within 2 days and who did
             not received drug administration

          5. Subjects who voluntarily or legal guardian agreed with written consent

        Exclusion Criteria:

          1. Fever reducer administration Within 4 hours from the screening point

          2. Any incidence of febrile crisis from the past six months

          3. Patinets with Ulcers, gastrointestinal disorders which are confirmed by endoscopy

          4. Patinets with continuously administrating gastrointestinal disorder related drug

          5. Patients with severe blood damage

          6. Severe hepatic impairment (ALT, AST value more than 2 times the upper limit of the
             normal range)

          7. With severe renal impairment (serum creatinine value is more than 2 times the upper
             limit of the normal range)

          8. Patients with severe left ventricular dysfunction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang University Hospital, South Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Hui Choi, pf.</last_name>
      <phone>+82 02-6299-2738</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelubi</keyword>
  <keyword>Pelubiprofen</keyword>
  <keyword>Loxoprofen</keyword>
  <keyword>Anti-pyretic</keyword>
  <keyword>Fever</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
